If MSB is able to bring a pharma partner that puts in significant cash to fund the needed trial(s) then I agree- if the long suffering shareholders have to fund any trial then things will be tough.
The really sad thing is the cells appear to work, but MSB got the trial designed wrong. I haven’t been following MSB closely for a while, but I have always suspected the original Osiris trial design would have been a success. There was a great video posted here by one of the clinical investigators talking about the history of this trial that is worth watching (sorry I don’t have the link).
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-126
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.030(1.90%) |
Mkt cap ! $1.832B | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.65 | $1.59 | $7.014M | 4.343M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 342 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 54534 | 8 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |